新一代减肥药物对癌症发病率的潜在影响。 - Suppr

Potential Impact of Next-Generation Weight Loss Drugs on Cancer Incidence.

作者信息

Brenner Darren R, Ruan Yibing, Carbonell Chantelle

机构信息

Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

出版信息

JAMA Netw Open. 2025 Sep 2;8(9):e2530904. doi: 10.1001/jamanetworkopen.2025.30904.

DOI:10.1001/jamanetworkopen.2025.30904

PMID:40920384

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12418124/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a288/12418124/591d084d1369/jamanetwopen-e2530904-g001.jpg

相似文献

Potential Impact of Next-Generation Weight Loss Drugs on Cancer Incidence.

JAMA Netw Open. 2025 Sep 2;8(9):e2530904. doi: 10.1001/jamanetworkopen.2025.30904.

The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.

Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.

Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model - A UK weight and wellness cancer landscape analysis.

Cancer Epidemiol. 2025 Aug;97:102837. doi: 10.1016/j.canep.2025.102837. Epub 2025 May 24.

Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.

Osteoporos Int. 2025 Sep 8. doi: 10.1007/s00198-025-07664-1.

The Impact and Safety of GLP-1 Agents and Breast Cancer.

Cancer Med. 2025 Jun;14(12):e70932. doi: 10.1002/cam4.70932.

Long-Term Impact of GLP-1 Receptor Agonists on AF Recurrence After Ablation in Obese Patients.

J Cardiovasc Electrophysiol. 2025 May 23. doi: 10.1111/jce.16737.

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.

Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

Obes Rev. 2025 Aug;26(8):e13929. doi: 10.1111/obr.13929. Epub 2025 Apr 4.

Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study.

EClinicalMedicine. 2025 May 11;83:103213. doi: 10.1016/j.eclinm.2025.103213. eCollection 2025 May.

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015.

本文引用的文献

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.

JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.

Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity.

N Engl J Med. 2019 Dec 19;381(25):2440-2450. doi: 10.1056/NEJMsa1909301.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Potential Impact of Next-Generation Weight Loss Drugs on Cancer Incidence.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Potential Impact of Next-Generation Weight Loss Drugs on Cancer Incidence.

作者信息

机构信息

出版信息

相似文献

本文引用的文献